Fig. 2From: A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in SpainMedian time to discontinuation for mirabegron versus antimuscarinics (base-case analysis; all eligible patients [N = 1798]). *Proportion of patients persistent at 12 months. CI, confidence intervals; HR, hazard ratio; TTD, time to discontinuationBack to article page